Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemiaRiccardo Moia, Gianluca Gaïdano, Carol Moreno et al.|Hematological Oncology|2022Cited by 4
Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic LeukemiaValentina Griggio, Marta Coscia, Candida Vitale et al.|Blood|2024Cited by 1
Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter TransformationChiara Cosentino, Riccardo Moia, Samir Mouhssine et al.|Blood|2024Cited by 1
Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control StudyAlberto Fresa, Luca Laurenti, Idanna Innocenti et al.|Blood|2024Cited by 0
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantationFrancesca Perutelli, Marta Coscia, Elia Boccellato et al.|British Journal of Haematology|2025Cited by 0